Friday , March 23 2018
Home / Tag Archives: Takeda (page 2)

Tag Archives: Takeda

April, 2017

January, 2017

  • 18 January

    Takeda and Ovid Partner for Development of Rare Pediatric Epilepsy Drug

    OSAKA, Japan & NEW YORK–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s …

  • 9 January

    Takeda to Acquire ARIAD Pharmaceuticals for $5.2 Billion

    CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) (“Takeda”) and ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) (“ARIAD”) today announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of …

December, 2016

October, 2016

September, 2016

August, 2016

June, 2016

February, 2016

  • 8 February

    Takeda Expands its ADC Collaboration with Mersana

    CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Mersana Therapeutics and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide …

November, 2015

  • 23 November

    FDA Approves Takeda’s Multiple Myeloma Pill

    Cambridge, Mass. and Osaka, Japan, November 20, 2015 – Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO®(ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple …